| 11788102 | CHO integration sites and uses thereof | Oct 17, 2023 |
| 11769597 | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF | Sep 26, 2023 |
| 11753459 | Anti-VEGF protein compositions and methods for producing the same | Sep 12, 2023 |
| 11732024 | VEGF antagonist formulations suitable for intravitreal administration | Aug 22, 2023 |
| 11707506 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jul 25, 2023 |
| 11559564 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jan 24, 2023 |
| 11555176 | Cell culture medium for eukaryotic cells | Jan 17, 2023 |
| 11548932 | Anti-VEGF protein compositions and methods for producing the same | Jan 10, 2023 |
| 11542317 | Anti-VEGF protein compositions and methods for producing the same | Jan 3, 2023 |
| 11535663 | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants | Dec 27, 2022 |
| 11485770 | Anti-VEGF protein compositions and methods for producing the same | Nov 1, 2022 |
| 11472861 | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants | Oct 18, 2022 |
| 11332771 | Serum-free cell culture medium | May 17, 2022 |
| 11312936 | Taurine supplemented cell culture medium and methods of use | Apr 26, 2022 |
| 11306135 | Anti-VEGF protein compositions and methods for producing the same | Apr 19, 2022 |
| 11299532 | Anti-VEGF protein compositions and methods for producing the same | Apr 12, 2022 |
| 11253572 | Use of a VEGF antagonist to treat angiogenic eye disorders | Feb 22, 2022 |
| 11174283 | Anti-VEGF protein compositions and methods for producing the same | Nov 16, 2021 |
| 11104715 | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants | Aug 31, 2021 |
| 11084865 | VEGF antagonist formulations suitable for intravitreal administration | Aug 10, 2021 |
| 11066458 | VEGF antagonist formulations suitable for intravitreal administration | Jul 20, 2021 |
| 11053280 | Anti-VEGF protein compositions and methods for producing the same | Jul 6, 2021 |
| 10927342 | Taurine supplemented cell culture medium and methods of use | Feb 23, 2021 |
| 10918754 | Sterilisation method | Feb 16, 2021 |
| 10905786 | Sterilisation method | Feb 2, 2021 |
| 10888601 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jan 12, 2021 |
| 10828345 | Use of a VEGF antagonist to treat angiogenic eye disorders | Nov 10, 2020 |
| 10669594 | Compositions and methods for detecting a biological contaminant | Jun 2, 2020 |
| 10464992 | VEGF antagonist formulations suitable for intravitreal administration | Nov 5, 2019 |
| 10415055 | Enhanced expression and stability regions | Sep 17, 2019 |
| 10130681 | Use of a VEGF antagonist to treat angiogenic eye disorders | Nov 20, 2018 |
| 09816110 | CHO integration sites and uses thereof | Nov 14, 2017 |
| 09562238 | Enhanced expression and stability regions | Feb 7, 2017 |
| 09315281 | System and methods for use in dispensing biopharmaceutical materials | Apr 19, 2016 |
| 09254338 | Use of a VEGF antagonist to treat angiogenic eye disorders | Feb 9, 2016 |
| 09222106 | Enhanced expression and stability regions | Dec 29, 2015 |
| 07070959 | Modified chimeric polypeptides with improved pharmacokinetic properties | Jul 4, 2006 |
